Pocenbrodib

DB21616InvestigationalSmall molecule

Pocenbrodib is a small molecule drug. Pocenbrodib is under investigation in clinical trial NCT06785636 (Open-Label Study of Pocenbrodib Alone and in Combination With Abiraterone Acetate, Olaparib, or 177Lu-PSMA-617). Pocenbrodib has... Pocenbrodib has a monoisotopic molecular weight of 525.23 Da.

Mechanism: Pharmacologically active on CREB-binding protein and Histone acetyltransferase p300
Curator reviewed
Formula / weight: C₂₈H₃₂FN₃O₆ · 525.577 g/mol (avg)
Code names: FT-7051

Resolves to

Compound

UNIIEI2N46W53ZCAS2304372-79-8ChEMBLCHEMBL5314476ChEBI759182PubChem138472434

Structure

InChIKeyNOUKMOKAEKAWKS-FSEQIFNCSA-NSMILESCOC(=O)N1[C@@H](C)CCC2=C3N=C([C@H](O)C4=C(OC)C=CC(F)=C4)N([C@@H]4CCC[C@H](C4)C(O)=O)C3=CC=C12

Targets

Q92793CREBBPQ09472EP300

What you can answer from here — as of September 23, 2026

2Protein targetsEach mapped to UniProt, with action and pharmacological action

Listed above

2Clinical trialsPhase, status and sponsor resolved per trial

2+ReferencesStructured and connected to the statements they support

Which drugs share a target with Pocenbrodib, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account